NCI Publications and Presentations

NCI-Authored Scientific Publications

2024

November 13, 2024: Samimi G, Temkin SM, Weil CJ, Han PKJ, LeeVan E, Rubinstein WS, Swigart TM, Caban S, Dent K, Minasian LM. Perceptions of multicancer detection tests among primary care physicians and loaypersons: a qualitative study. Cancer Medicine 2024 Nov;13(21):e70281. doi: 10.1002/cam4.70281. PMID: 39475101; PMCID: PMC11523003.

October 9, 2024: Hu P, Prorok PC, Katki HA. Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screening. Journal of the National Cancer Institute. 2024 Oct 9:djae247. doi: 10.1093/jnci/djae247. Epub ahead of print. PMID: 39383209.

October 1, 2024: Katki HA, Prorok PC, Castle PE, Minasian LM, Pinsky PF. Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening. Journal of the National Cancer Institute. 2024 Oct 1;116(10):1675-1682. doi: 10.1093/jnci/djae218. PMID: 39267581.

September 2, 2024: Samimi G, Temkin SM, Weil CJ, Han PK, LeeVan E, Rubinstein WS, Swigart T, Caban S, Dent K, Minasian LM. Primary care physicians and laypersons' perceptions of multicancer detection clinical trial designs. JNCI Cancer Spectrum 2024 Sep 2;8(5):pkae084. doi: 10.1093/jncics/pkae084. PMID: 39270066; PMCID: PMC11463188.

August 2024: Clarke CA, Mitchell BL, Putcha G, et al. Lexicon for blood‐based early detection and screening: BLOODPAC consensus document. PubMed Central. PMCID: PMC11358766, PMID: 39206679.

July 4, 2024: Ramos MLF, Chaturvedi AK, Graubard BI, Katki HA. Efficient risk-based collection of biospecimens in cohort studies: Designing a prospective study of diagnostic performance for multicancer detection tests. American Journal of Epidemiology. 2024 Jul 4:kwae139. doi: 10.1093/aje/kwae139. Epub ahead of print. PMID: 38965750.

March 22, 2024: Rubinstein WS, Patriotis C, Dickherber D, Han PKJ, Katki HA, LeeVan E, Pinsky PF, Prorok PC, Skarlupka AL, Temkin SM, Castle PE, Minasian LM. Cancer screening with multicancer detection tests: A translational science review. CA: A Cancer Journal for Clinicians (2024). doi: 10.3322/caac.21833.

February 8, 2024: Etzioni R, Gulati R, Patriotis C, Rutter C, Zheng Y, Srivastava S, Feng Z. Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologies. Journal of the National Cancer Institute, 2024 Feb 8;116(2):189-193. doi: 10.1093/jnci/djad227. PMID: 37941446; PMCID: PMC10852609.

2023

October 4, 2023: LeeVan E, Pinsky P. Predictive performance of cell-free nucleic acid-based multi-cancer early detection tests: a systematic review. Clinical Chemistry, Volume 70, Issue 1, January 2024, Pages 90–101. doi: 10.1093/clinchem/hvad134.

March 9, 2023: Minasian LM, Pinsky P, Katki HA, Dickherber T, Han PKJ, Harris L, Patriotis C, Srivastava S, Weil CJ, Prorok PC, Castle PE. Study design considerations for trials to evaluate multicancer early detection assays for clinical utility.  Journal of the National Cancer Institute. 2023 Mar 9;115(3):250-257. doi: 10.1093/jnci/djac218. PMID: 36458902; PMCID: PMC9996206.

2022

December 22, 2022: Minasian, L Pinsky, P, et al. Study design considerations for trials to evaluate multi-cancer early detection assays for clinical utility. Journal of the National Cancer Institute, 2022; djac218. PMID: 36458902; PMCID: PMC9996206.

NCI Presentations

October 28, 2024: DCP Participation in National Academies of Science Engineering, and Medicine (NASEM) MCD Workshop: Opportunities and Challenges for the Development and Adoption of Multicancer Detection Tests – October 28-29, 2024 | Division of Cancer Prevention.

June 11, 2024: Inside Precision Medicine Special Webinar: Unlocking the Potential of Multicancer Detection Tests: Insights and Real-World Applications. Rubinstein and Patriotis.

April 7, 2024: AACR 2024 Annual Meeting. Co-Chair, Mini symposium. Top 7 abstracts presented, co-chair with Marie Wood, Alliance for Clinical Trials in Oncology.

April 6, 2024: American Association of Cancer Research (AACR) 2024 Annual Meeting, San Diego CA. Platform presentation and panelist, Using risk to define intended-use populations. Hosted by BloodPAC: Educational Session DC06: Rethinking Risk and Risk Assessment for Liquid Biopsy-Based Single- and Multi- Cancer Screening.

March 28, 2024: Nebraska Cancer Coalition Cancer Summit. Keynote: Tailoring Healthcare: The Precision Medicine Revolution is Here.

January 25, 2024: Precision Medicine World Conference, Santa Clara CA. Platform presentation and panelist, NCI’s Cancer Screening Research Network and Vanguard study. Moderator Tom Beer, Exact Sciences; co-panelist Sheila Walcoff, Goldbug Strategies.

News Stories

2024

December 2, 2024: A Deep Dive into Awareness and Perceptions of Potential Benefits and Harms of Multi-Cancer Detection Tests | Division of Cancer Prevention

2023

November 1, 2023: Multicancer Detection Assays Promise to Improve Cancer Screening. But Do They Work? ASCO Daily News

May 30, 2023: Cancer HealthCast: Emerging Technologies are Showing Promise in Early Cancer Detection | GovCIO Media & Research